What is BiVACOR?
Founded in 2008, BiVACOR operates at the intersection of advanced engineering and life-saving medical intervention. The company specializes in the development of a Total Artificial Heart (TAH), a device designed to replace the function of a failing heart. By integrating world-class engineering talent with clinical expertise, BiVACOR has established a robust international network dedicated to solving the critical shortage of donor organs. Their market position is defined by high-barrier-to-entry innovation, where the focus remains on rigorous testing, regulatory compliance, and the refinement of its core technology to meet the complex physiological demands of patients suffering from end-stage heart failure.
How much funding has BiVACOR raised?
BiVACOR has raised a total of $22M across 2 funding rounds:
Series B
$19M
Grant
$3M
Series B (2021): $19M with participation from Cormorant Asset Management and OneVentures
Grant (2021): $3M led by National Heart, Lung, and Blood Institute at the U.S. National Institute of Health
Key Investors in BiVACOR
Cormorant Asset Management
A prominent life sciences investment firm that provides financial resources to support innovative private and publicly traded companies in the biotech and allied sectors.
OneVentures
A venture capital firm focused on identifying and scaling high-growth technology and healthcare companies with significant market potential.
National Heart, Lung, and Blood Institute at the U.S. National Institute of Health
A federal research institution providing critical grant funding to support scientific breakthroughs and public health advancements in cardiovascular medicine.
What's next for BiVACOR?
Looking ahead, the infusion of capital will likely be directed toward scaling manufacturing capabilities and navigating the final stages of clinical trials. As BiVACOR transitions from a research-heavy entity to a commercial-stage medical device manufacturer, the strategic focus will shift toward regulatory approval processes and establishing a global supply chain. The company is expected to prioritize the optimization of its device for long-term durability and patient comfort, while simultaneously expanding its collaborative network with leading cardiovascular centers. This phase of development is critical for validating the clinical efficacy of their technology, ultimately aiming to provide a sustainable alternative to heart transplantation in a global market that remains underserved by existing mechanical circulatory support solutions.
See full BiVACOR company page
